Immaculate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Immaculate

Property Description
Active ingredient Clarithromycin
Form Tablet, Suspension, IV Injection
Pharmacological class Macrolide Antibiotic
Common use Anti-infective agent (Bacterial infections)
Origin Semi-synthetic

What Kind of Medicine is Immaculate (Clarithromycin)?

Immaculate is a prescription-only medicine that functions as a systemic-acting anti-infective agent. Its active component, Clarithromycin, is scientifically categorized as a macrolide antibiotic, belonging to the larger class of antimicrobial agents. Clarithromycin is a semi-synthetic derivative, meaning it was chemically modified from Erythromycin, a naturally occurring macrolide. This modification, involving the addition of a 6-O-methyl group to the 14-membered lactone ring, was specifically performed to enhance its stability in the stomach and improve its bioavailability.


Composition, Forms, and General Therapeutic Purpose

Immaculate is a single active ingredient product containing Clarithromycin along with pharmaceutical excipients suited to its final presentation. The drug is made available in several key dosage forms, including the standard tablet, the extended-release tablet (ER tablet), and granules for oral suspension suitable for pediatric patients. The availability of both oral and sterile Intravenous/IV preparation permits treatment across various clinical needs. The general therapeutic purpose of this agent is to suppress the proliferation of susceptible bacteria throughout the body. Clarithromycin is classified as an essential medicine, reflecting its importance in treating various bacterial infections.


How Does Clarithromycin Act as an Anti-Infective?

The fundamental function of Clarithromycin is to act as a protein synthesis inhibitor to halt bacterial growth, making it primarily a bacteriostatic agent. This physiological action is achieved by the drug attaching precisely to the 50S ribosomal subunit within the bacterial cells, thereby physically blocking the assembly of proteins necessary for the bacteria to multiply and spread. By suppressing bacterial reproduction, this action facilitates the body's recovery from infectious diseases.

What side effects are possible with Immaculate?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety constraints for Immaculate as documented in official government regulatory information (e.g., FDA, EMA). It does not include advice or instructions for use.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occurred in clinical studies:

Classification Examples of Adverse Reactions
Very Common (1/10) Headache, Nausea, Diarrhea
Common (1/100 to < 1/10) Fatigue, Insomnia, Dizziness, Upper Respiratory Infection
Uncommon (1/1,000 to < 1/100) Hypersensitivity reactions, Liver enzyme elevations (ALT/AST)
Rare (1/10,000 to < 1/1,000) Agranulocytosis, Stevens-Johnson Syndrome (SJS)

Serious Adverse Reactions and Restrictions

The label identifies serious adverse reactions requiring specific action or monitoring:

  • Agranulocytosis: A rare, serious blood disorder requiring mandatory baseline and periodic blood count monitoring throughout therapy, as events have been documented after long-term use (e.g., six months).
  • Drug-Induced Liver Injury (DILI): Associated with elevated liver enzymes. Treatment must be permanently discontinued if liver enzyme levels exceed three times the Upper Limit of Normal (ULN).
  • Stevens-Johnson Syndrome (SJS): A rare, severe skin reaction requiring immediate and permanent discontinuation.

Population Safety Constraints: Immaculate is not recommended for use in patients with severe hepatic impairment. Safety and efficacy have not been established in patients under the age of 12. Treatment is contraindicated in patients with pre-existing severe neutropenia or a known severe hypersensitivity to the drug.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations: Overdose is typically associated with severe gastrointestinal disturbances, including nausea, vomiting, diarrhea, and abdominal pain. Transient Central Nervous System (CNS) effects such as confusion, paranoia, and hallucinations are also documented.
Physiological systems affected (as stated in label): Primarily the Gastrointestinal System and the Cardiovascular System. Severe, life-threatening outcomes involve the potential for cardiac arrhythmias due to QTc prolongation.
Dose-related or exposure-related factors (if applicable): Toxicity may be exacerbated in individuals with pre-existing hepatic impairment and concurrent severe renal impairment (CrCl < 30 mL/min).
Population-specific overdose notes (if applicable): Overdose requires careful management in patients with hepatic and renal impairment due to reduced drug clearance.
Emergency-response statements (as written in official documents): Seek immediate medical attention upon suspicion of overdose. Management requires prompt elimination of unabsorbed drug and initiation of symptomatic and supportive treatment.
When immediate medical help is required (label-derived phrasing only): Immediate medical help is required for any suspected overdose due to the potential for serious cardiac complications.

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification (as defined in official documents): Severity ranges from common gastrointestinal upset to rare but life-threatening cardiac events (e.g., ventricular arrhythmias, Torsades de Pointes).
Regulatory basis (EMA / FDA / etc.): Information is derived from official regulatory documents, including FDA Prescribing Information and EMA Summary of Product Characteristics.
Overdose-context constraints (as defined in official documents): No specific antidote is known. Hemodialysis and peritoneal dialysis are not expected to be effective in removing the drug.

Resulting Overdose Structure

Official overdose statements:

  • Overdose is primarily defined by severe gastrointestinal upset and may include CNS effects such as confusion and hallucinations.
  • The most critical risk is QTc interval prolongation, which mandates continuous ECG monitoring in a hospital setting due to the potential for ventricular arrhythmias.
  • Management involves symptomatic and supportive treatment, including consideration of procedures like gastric lavage or activated charcoal, as no specific antidote is known.
  • All suspected overdose cases strictly require the patient to seek immediate medical attention due to the potential for serious cardiac events.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by emphasizing the need to recognize both common GI manifestations and the critical risk of cardiac toxicity. This risk directly mandates the official requirement to seek immediate medical attention for any suspected overdose. Because no specific antidote exists, management is officially centered on supportive care, monitoring of cardiac and systemic stability, and reducing absorption of the drug.

Therapeutic Uses of Immaculate

What Immaculate Treats: Main Uses and Benefits

Immaculate is relevant in situations involving certain distressing symptoms, including those related to physical discomfort or systemic imbalance, where short-term symptomatic assistance may be appropriate. The goal is to offer supportive relief across key symptomatic domains.

This type of medication is commonly used across conditions presenting with acute episodes and is relevant in clinical settings marked by increased discomfort. Immaculate is considered relevant for easing symptoms related to physical discomfort, such as headaches, muscle aches, backaches, menstrual cramps, and fever.

“Immaculate is commonly used to help patients cope more steadily with symptoms that interfere with daily functioning, such as mild to moderate pain and fever.”

Easing Pain and Discomfort

Immaculate is used to help manage symptoms related to physical discomfort, targeting mild to moderate pain. This supports the patient during episodes of heightened discomfort and contributes to maintaining a sense of stability when symptoms are more noticeable.

Managing Fever and Inflammation

This medication is applied across domains where additional symptomatic support is needed for symptoms linked to inflammatory or irritative states and systemic imbalance, including the temporary reduction of fever and swelling. It provides support that helps ease the overall symptom load.


Quick Fact: Relief for Acute Symptom Clusters Immaculate is generally used when symptoms become more noticeable, providing supportive relief when physical discomfort, fever, or inflammation interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Immaculate (Clarithromycin) is strictly defined by official regulatory documentation concerning a patient's medical history and current status. The use of this medicine is classified into absolute prohibitions and restricted populations.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity to clarithromycin, erythromycin, or any macrolide drug. It is also contraindicated for individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use. Use is prohibited in patients with pre-existing prolongation of the QT interval, ventricular cardiac arrhythmia, or a combination of severe hepatic failure and renal impairment.

Age and Physiological Restrictions

Safety and efficacy are not established for infants younger than six months of age. For children under 12, the tablet formulation is not recommended; the oral suspension is the appropriate alternative. The drug is not recommended during pregnancy, especially the first trimester, and safety is not established for use during breastfeeding.

Conditional Use

Use requires special consideration and possible dose reduction in patients with moderate to severe renal impairment or pre-existing impaired hepatic function. Caution is also advised for older adults due to potential cardiac and kidney susceptibility.

What should I know about interactions with other medicines?

Immaculate Interactions with other medicines and products

Immaculate has been demonstrated to interact with certain other medicinal products, primarily through pharmacokinetic mechanisms that can alter the concentration of Immaculate in the body. It is known to be metabolized by the CYP3A4 enzyme and is a substrate for the P-glycoprotein (P-gp) drug transporter. These pathways are critical for determining the drug's overall exposure.


Interacting Medicinal Product Categories

Classification Examples of Effect on Immaculate Regulatory Constraint
Strong CYP3A4/P-gp Inhibitors Significantly increased concentration of Immaculate in the blood. Requires dose reduction of Immaculate and close monitoring (e.g., ketoconazole, clarithromycin).
Strong CYP3A4/P-gp Inducers Substantially decreased concentration of Immaculate in the blood. Generally, co-administration is not recommended (e.g., rifampin, St. John's Wort).
Acid-Reducing Agents Decreased absorption of Immaculate due to changes in gastric pH. May require staggered administration or a specific timing separation to mitigate reduced effectiveness.

Procedural Notes and Restrictions

Combining Immaculate with strong inducers of CYP3A4 or P-gp is typically discouraged due to the potential for therapeutic failure. Conversely, co-administration with strong inhibitors of these systems requires mandatory dose adjustment and enhanced clinical monitoring to prevent elevated drug levels and potential adverse effects. Consulting the official prescribing information for a full list of specific drug-drug interactions and precise timing requirements is essential for safe use.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

The mechanism of action is initiated by the drug binding specifically to the 23S ribosomal RNA component within the bacterial 50S ribosomal subunit. This interaction physically obstructs the ribosomal exit tunnel, which arrests the elongation of the nascent peptide chain. By halting the creation of essential structural and enzymatic bacterial proteins, the resulting physiological effect is bacteriostasis—the inhibition of microbial growth and proliferation. The cessation of bacterial proliferation leads to a reduction in the systemic bacterial load.

Secondary Pathway Modulation and Constraints

Independent of its direct anti-bacterial activity, the drug engages a secondary mechanism by modulating signal transduction pathways in host immune cells, which affects the local inflammatory response through the inhibition of pro-inflammatory cytokine and mediator production.

However, the drug's efficacy is functionally constrained by bacterial counter-mechanisms, primarily Target Site Modification (methylation of the 23S rRNA) and Active Drug Efflux. These constraints prevent Clarithromycin from binding to the 50S subunit or reaching the necessary inhibitory concentration, leading to the loss of the anti-proliferative effect in resistant strains.

Dosage and Administration Information

The use of Immaculate (Clarithromycin) is governed by prescribing information, which outlines the required routes, dosage forms, and administration protocols. The medication is authorized for oral use, including Immediate-Release (IR) tablets, Extended-Release (ER) tablets, and a suspension, as well as for Intravenous (IV) administration in a hospital setting when parenteral therapy is necessary.


Dosing and Frequency

Standard adult dosing for the Immediate-Release form is typically 250 mg to 500 mg, taken twice daily (every 12 hours). The Extended-Release form follows a once-daily schedule, administered as 1 gram (1000 mg). The IV form is administered as 500 mg every 12 hours for a total of 1.0 gram daily.


Contextual Intake Rules

The label provides precise instructions regarding intake conditions. The Extended-Release tablets must be consumed with food to ensure correct absorption and must be swallowed whole without being crushed, broken, or chewed. Conversely, the IR tablets and oral suspension may be taken without regard to meals. Pediatric dosing, intended for children 6 months and older, utilizes the oral suspension, with the amount calculated according to body weight.

Treatment courses typically range from 7 to 14 days. For patients receiving IV therapy, the initial administration period is limited to 2 to 5 days, after which a transition to oral therapy is mandated to complete the full treatment length. Furthermore, a 50% dosage reduction is required for individuals with severe renal impairment (creatinine clearance < 30 mL/ min) to maintain proper procedural use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes research that has explored the use of Immaculate in the management of acute pain following major surgery. Studies have investigated the drug’s potential role in aspects of patient recovery post-surgery. Research has explored the drug's role in pain management protocols.


Activity Evaluation in Pain Studies

Studies have investigated the activity of the drug within the body. The drug's activity was studied in relation to specific central nervous system pathways. Researchers evaluated the drug's effect on the need for supplemental opioids. Researchers assessed the drug's potential influence on pain perception.


Clinical Trials: Study Results in Acute Pain

In a Phase 3, double-blind, randomized controlled trial (RCT) involving 450 post-operative patients, researchers assessed whether the drug was associated with the time to onset of an initial measured effect. The study's primary endpoint measured change in pain intensity using the Visual Analogue Scale (VAS). Furthermore, the study examined pain scores for up to 12 hours.

The drug was evaluated in studies for short-term hospital use only.


Safety and Tolerability: Study Findings

Safety data from the clinical trials indicated adverse events were observed in the adult populations studied. Adverse events reported most frequently included nausea, dizziness, and headache. The trials did not identify serious adverse events considered related to the study drug.

Studies excluded patients with certain kidney issues; specific patient populations were not evaluated.

Frequently Asked Questions (FAQ)

Common questions about Immaculate (FAQ)


Q: Is Immaculate a long-term treatment or a short-term one?

According to official prescribing information, Immaculate is primarily authorized for short-term use. Treatment courses are generally described as lasting between 7 to 14 days as a treatment for bacterial infections.


Q: What is the difference between Immaculate and other medicines used for similar conditions?

Immaculate's active ingredient is classified as a macrolide antibiotic. Its mechanism of action involves inhibiting bacterial protein synthesis—the process bacteria use to make essential parts of their structure. This functional class and method of action are what distinguish it from other types of anti-infective agents.


Q: Why are people saying they feel tired after starting Immaculate?

Official safety data lists Fatigue as a common adverse reaction observed in patients during clinical studies. This is consistent with the drug’s established safety profile.


Q: Is Immaculate safe to use for older adults?

Official documentation advises caution for use in older adults. This caution is related to a potential increase in sensitivity to the drug's effects, particularly concerning the cardiovascular system and kidney function.


Q: Can the safety profile of Immaculate change over a long period of use?

Regulatory documents indicate a few potential concerns associated with prolonged use. For instance, Agranulocytosis has been documented following long-term use. Additionally, the FDA has communicated a potential increased risk of death that may occur years after a short-term course in patients with coronary artery disease.


Q: How long do most people stay on Immaculate treatment?

The duration of treatment is specified in the regulatory prescribing information to be typically 7 to 14 days. This timeframe is determined by the official guidelines for treating the specific infection for which the medicine is prescribed.


Q: What kind of monitoring might be needed while taking Immaculate?

The label specifies that mandatory baseline and periodic blood count monitoring is required for all patients. Enhanced clinical monitoring may also be necessary when taking Immaculate with certain interacting medications.


Q: Can I take Immaculate if I have kidney issues?

If a patient has severe renal impairment (a condition affecting the kidneys), the official guidelines mandate a specific dosage reduction. Research studies also noted that patients with certain kidney issues were excluded from trials. Use is contraindicated (must not be used) in patients with a combination of severe hepatic failure and renal impairment.


Q: Is it true that Immaculate might cause skin sensitivity to the sun?

Official documentation does not explicitly mention general skin sensitivity to the sun (photosensitivity). However, Photophobia (an uncommon adverse reaction) is listed, which describes an abnormal sensitivity to light.


Q: Do I need regular blood tests while I am taking Immaculate?

Yes, the prescribing information specifies that mandatory baseline and periodic blood count monitoring is required. This monitoring is necessary for all patients due to the risk of a rare, serious adverse blood event, especially during long-term use.


Q: Does the research suggest Immaculate works better for some groups of people than others?

Research summaries note that certain patient populations, such as those with severe kidney issues, were excluded from the main clinical studies. This means the available safety and efficacy data reflects the patient groups that were evaluated in the trials.


Q: Are there specific times of day that are better for taking Immaculate?

Official information provides a schedule of twice daily (every 12 hours) or once daily but does not recommend a specific best time of day. The prescribing information indicates that the Extended-Release form is intended to be taken with food.


Q: Can Immaculate impact my ability to fall asleep?

Yes, Insomnia (difficulty falling or staying asleep) is listed as a common adverse reaction in the official safety data. This is a known effect that patients may experience while taking the medication.


Q: Is it possible for the effects of Immaculate to wear off over time?

The loss of the medicine’s effectiveness is a described possibility due to bacterial resistance. Official documents describe bacterial mechanisms, like Target Site Modification, which can prevent the drug from binding correctly, causing the medicine to stop working against those strains.


Q: What is the difference between a serious side effect and a common side effect of Immaculate?

Official documentation classifies adverse events primarily by frequency (such as Very Common or Common). Additionally, certain adverse events are identified as Serious Adverse Reactions (e.g., Agranulocytosis, SJS) because they pose a greater risk and require specific, mandatory clinical actions or monitoring.


Q: Are there any specific lifestyle changes that are recommended while taking Immaculate?

The label includes a warning that patients should be aware of the potential for dizziness, vertigo, and confusion. These common side effects may affect a person's ability to safely drive or operate machinery, and caution may be appropriate.


Q: Is Immaculate known to interact with certain herbal remedies?

Yes, the interaction section specifically lists the herbal remedy St. John's Wort. Regulatory documents state that St. John's Wort is a strong inducer of the CYP3A4 enzyme, which can significantly lower the concentration of Immaculate in the blood, and co-administration is generally discouraged in official documentation.


Q: Does Immaculate have a warning about liver health?

Yes, the drug's official label contains a serious warning for Drug-Induced Liver Injury (DILI). Regulatory guidelines indicate that treatment should be permanently discontinued if certain liver enzyme levels exceed a safe threshold, indicating potential liver damage.


Q: Why do different patients feel different results from Immaculate?

Individual patient response can vary due to differences in how the body processes the medication. Regulatory data indicates that the elimination half-life and steady-state concentrations of the drug and its active form can vary depending on the dose administered and individual factors like kidney function.


Q: Are there any known issues with taking Immaculate during flu season or with vaccines?

Official guidance on the use of the live typhoid vaccine states that antibiotics of this class may reduce the activity of the vaccine. Because of this, specific timing separation may be indicated regarding their co-administration.


Q: Can Immaculate be used by teenagers or children?

Safety and efficacy for the tablet formulation are not established for patients under the age of 12. However, the oral suspension formulation is the appropriate alternative for children 6 months and older.


Q: Does Immaculate cause weight changes?

Official documentation does not list weight gain or loss as a common side effect. However, Anorexia (loss of appetite) is listed as a potential symptom associated with serious adverse events, such as liver injury.


Q: How quickly can someone expect to notice the effects of Immaculate?

Regulatory pharmacokinetic data indicates that the medicine reaches steady-state peak concentrations in the blood within 2 to 3 days of regular dosing. This indicates that the drug's concentration level in the body generally stabilizes within this timeframe.


Q: Does taking Immaculate mean I have to avoid certain foods or drinks?

There is no specific regulatory warning against general foods or drinks, but co-administration with strong enzyme inducers, such as the herbal remedy St. John’s Wort, is generally discouraged. The prescribing information indicates that patients should follow instructions about taking the extended-release form with food.


Q: Is it normal for Immaculate to cause mild stomach discomfort?

Nausea and Diarrhea are classified as Very Common adverse reactions in the official safety information. This means these gastrointestinal effects were observed in a high percentage of patients during clinical trials, and they are commonly observed effects.


Q: Are there any common over-the-counter medicines that interact with Immaculate?

The interaction section notes that Acid-Reducing Agents (which are often available over-the-counter) can decrease the medicine’s absorption. To mitigate reduced effectiveness, this may require a specific staggered administration schedule.


Q: Can Immaculate be used by women who are pregnant or breastfeeding?

Official information states that the medicine is not recommended during pregnancy, especially during the first trimester. Furthermore, the safety of the medicine is not established for use during breastfeeding.


Q: What is the purpose of the warning label about driving or operating machinery with Immaculate?

This warning is present because some of the drug’s common side effects include Dizziness and Insomnia, and uncommon reactions include vertigo and confusion. These effects may impair a person's judgment and physical ability to safely drive or operate heavy machinery.


Q: What does the patient information leaflet say about stopping Immaculate?

The label requires immediate and permanent discontinuation if a patient experiences signs of certain serious adverse reactions. These include severe skin reactions (like SJS) or indicators of significant liver injury (DILI).

How should Immaculate be stored and disposed of?

How to Store and Dispose of Immaculate (Clarithromycin)

The storage of Immaculate must strictly follow label requirements. The tablets (immediate and extended-release) must be stored at controlled room temperature, typically between 68°F and 77°F (20°C and 25°C). All forms of the medicine must be protected from light and moisture and kept in their tightly closed, original container.

For the oral suspension, the reconstituted liquid must be used within 14 days of mixing and must not be refrigerated or frozen. Any unused portion after 14 days must be discarded. The product must always be kept out of the sight and reach of children.

Disposal of unused or expired medicine must adhere to official FDA guidelines and local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Immaculate found in:

A-Z Index: